

Location: University of South Carolina College of Pharmacy
Coker Life Sciences Building Room 215, 715 Sumter Street, Columbia, SC 29208

Target Audience: Pharmacists and Pharmacy Technicians

Topics & Faculty: See page 2 for full program agenda and learning objectives!

Live Programming (6 hours)



Drugs of Abuse: A Focused Update on Abuse and Monitoring

Jordan Cooler, PharmD, BCPP
Clinical Assistant Professor, UofSC COP;
Psychiatric Pharmacist, UofSC Student Health Center



Hypertension: Classification, Management, and Monitoring of the Most Common Disease State

Julie Sease, PharmD, FCCP
Senior Associate Dean and Professor, UofSC COP



Determining Decisions and Deciphering Dilemmas in Dyslipidemia with Updated American College of Cardiology/American Heart Association Cholesterol Guidelines

Cynthia Phillips, PharmD, CDE
Clinical Associate Professor, UofSC COP;
Clinical Pharmacist, Prisma Health Richland



Beyond Diabetes: Benefits of SGLT2 Inhibitors and GLP-1 Agonists

Brie Dunn, PharmD
Associate Dean for Outcomes Assessment & Accreditation and Clinical Associate Professor; UofSC COP



Community Acquired Pneumonia Update

Hana Rac Winders, PharmD, BCIDP
Lead Antimicrobial Stewardship Pharmacist, Antimicrobial Stewardship Collaborative of South Carolina (ASC-SC);
Clinical Assistant Professor, UofSC COP



Management of Pit Viper and Black Widow Envenomation

Jill Michels, PharmD, DABAT
Clinical Associate Professor, UofSC COP
Managing Director, Palmetto Poison Center

Home Study Programming Available to All Registrants (1 hour)



Immunized People 2020: An Immunization Update

Kathryn N. Anderson, PharmD
PGY1 Community Pharmacy Resident,
Medicine Mart Pharmacy

Registration: Register online at <https://cop.sc.learningexpressce.com>
Registration will remain open until **Friday, February 14, 2020 at 8:00 am**

Note: Fees include continental breakfast and lunch

	Pharmacists**	Pharmacy Technicians
Single day, prior to January 6, 2020*	\$130	\$85
Both days (2/1 and 2/22), prior to January 6, 2020*	\$230	\$140

*All registration fees will increase by \$20 after January 6, 2020.

**PEEP Preceptors: Check your email for information from the PEEP Office on discounted registration!

Fees will appear as "Learning Express" on your credit card statement

Cancellations: UofSC COP reserves the right to cancel the entire program. In the event of a cancellation, each participant will be notified via email prior to the program and a full tuition refund will be made. All refunds should be requested in writing on or before January 17, 2020 and will be subject to a 7.5% administrative fee. No cancellation requests will be accepted after January 17, 2020.

Accreditation: The University of South Carolina College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.



This program has been accredited for 6.0 live contact hours (0.6 CEUs) and 1.0 home study contact hour (0.1 CEU) for pharmacists and pharmacy technicians. Six live hours qualify as "drug therapy or patient management", with one of those hours designed to combat the opioid epidemic through pain management and "approved procedures for monitoring controlled substances". The home study hour serves as an immunization update for immunizing pharmacists and will qualify as "drug therapy or patient management".

Participants must sign in at the program and have attendance verified. Participants must complete online evaluations within 30 days to facilitate transmission to the CPE Monitor. Failure to provide correct and/or complete information may result in your activity not being reported to the CPE Monitor. ACPE requires that all credit be claimed and reported within 60 days after the live event or completion of the home study.

Full Program Agenda and Learning Objectives:

8:00 am-8:30 am: Registration/Check-In and Welcome (<i>Light continental breakfast provided</i>)	
8:30 am-9:30 am 	<p align="center">Drugs of Abuse: A Focused Update on Abuse and Monitoring Jordan Cooler, PharmD, BCPP (1.0 hours, ACPE UAN 0062-0000-20-007-L01-P/T, application-based)</p> <p><i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Identify risk factors for inappropriate use of controlled substances and other prescription and non-prescription drugs of abuse 2. Explain best practices for identifying and mitigating drug abuse and misuse based on available data 3. Apply recommendations in a specific pharmacy practice setting
	<p><i>At the completion of this activity, the technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Describe best practices for identifying and mitigating drug abuse and misuse based on available data
9:30 am-9:45 am: Break	
9:45 am-10:45 am 	<p align="center">Hypertension: Classification, Management, and Monitoring of the Most Common Disease State Julie Sease, PharmD, FCCP (1.0 hours, ACPE UAN 0062-0000-20-008-L01-P/T, application-based)</p> <p><i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Use patient case information to categorize a patient as having normal blood pressure, elevated blood pressure, stage 1 hypertension, or stage 2 hypertension and assign an appropriate evidence based blood pressure goal for the patient 2. Recommend an appropriate initial evidence based treatment plan (including nonpharmacologic and pharmacologic therapies) for a patient based on their presenting blood pressure value and patient specific factors (including compelling indications, laboratory evaluation, and ASCVD risk) 3. Justify an appropriate evidence based treatment plan for a patient who is not meeting blood pressure goal on their current regimen 4. Educate a patient who will be conducting home blood pressure monitoring about the guideline-recommended way to complete this
	<p><i>At the completion of this activity, the technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Identify blood pressure measurements that fall into the following categories: normal blood pressure, elevated blood pressure, stage 1 hypertension, or stage 2 hypertension 2. Name antihypertensive classes that are used as initial treatment in patients with hypertension and state nonpharmacologic recommendations that may be made to help a patient lower their blood pressure 3. Recognize appropriate pharmacotherapeutic modifications that might be made for a patient taking antihypertensive therapy when their initial regimen fails to get them to their blood pressure goal 4. Educate a patient who will be conducting home blood pressure monitoring about the guideline-recommended way to complete this
10:50 am-11:50 am 	<p align="center">Determining Decisions and Deciphering Dilemmas in Dyslipidemia with Updated American College of Cardiology/American Heart Association Cholesterol Guidelines Cynthia Phillips, PharmD, CDE (1.0 hours, ACPE UAN 0062-0000-20-009-L01-P/T, application-based)</p> <p><i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Investigate patient risk of atherosclerotic cardiovascular disease (ASCVD) using risk calculators and risk enhancing factors 2. Analyze updates in the American College of Cardiology (ACC)/American Heart Association (AHA) Cholesterol Guidelines 3. Discuss the appropriate use of non-statin therapies in ASCVD prevention 4. Apply updated ACC/AHA Cholesterol Guidelines to patient cases
	<p><i>At the completion of this activity, the technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Identify specific indications for statin and non-statin therapies in patients with atherosclerotic cardiovascular disease (ASCVD) 2. Discuss issues that require pharmacist intervention in patients with ASCVD 3. Identify potential sources of error with use of statin and non-statin therapies
11:50 am-12:45 pm: Lunch (<i>Provided</i>)	
12:45 pm-1:45 pm 	<p align="center">Beyond Diabetes: Benefits of SGLT2 Inhibitors and GLP-1 Agonists Brie Dunn, PharmD (1.0 hours, ACPE UAN 0062-0000-20-010-L01-P/T, application-based)</p> <p><i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Describe the advantages and disadvantages of SGLT2 inhibitors and GLP-1 agonists 2. Identify potential benefits of SGLT2 inhibitors and GLP-1 agonists based on recent clinical trial data 3. Compare and contrast cardiovascular and renal benefits for available SGLT2 inhibitors and GLP-1 agonists 4. Develop and justify an evidence-based plan for a specific patient in order to provide cardiovascular and/or renal benefit. given a case scenario
	<p><i>At the completion of this activity, the technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Describe the advantages and disadvantages of SGLT2 inhibitors and GLP-1 agonists 2. Identify potential benefits of SGLT2 inhibitors and GLP-1 agonists based on recent clinical trial data 3. Compare and contrast cardiovascular and renal benefits for available SGLT2 inhibitors and GLP-1 agonists
1:45 am-2:00 pm: Break	
2:00 pm – 3:00 pm 	<p align="center">Community Acquired Pneumonia Update Hana Rac Winders, PharmD, BCIDP (1.0 hours, ACPE UAN 0062-0000-20-011-L01-P/T, application-based)</p> <p><i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Identify the differences between the 2007 and 2019 community-acquired pneumonia (CAP) guidelines 2. Discuss the evidence behind recommendations in the new CAP guidelines 3. Apply the new CAP guidelines to patient cases 4. Recognize the pharmacist's role in antimicrobial stewardship relating to the treatment of CAP
	<p><i>At the completion of this activity, the technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Identify the differences between the 2007 and 2019 community-acquired pneumonia (CAP) guidelines 2. Discuss the recommendations in the new CAP guidelines 3. Recognize the pharmacy technician's role in antimicrobial stewardship relating to the treatment of CAP
3:05 pm – 4:05 pm 	<p align="center">Management of Pit Viper and Black Widow Envenomation Jill Michels, PharmD, DABAT (1.0 hours, ACPE UAN 0062-0000-20-012-L01-P/T, application-based)</p> <p><i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Discuss treatment myths associated with pit viper envenomation. 2. Recommend supportive treatment for pit viper envenomation. 3. Compare Crotalidae Polyvalent Immune Fab (Ovine) antivenom to Crotalidae Immune F(ab)² (Equine) antivenom 4. List treatment options for black widow spider bite
	<p><i>At the completion of this activity, the technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Discuss treatment myths associated with pit viper envenomation 2. Compare Crotalidae Polyvalent Immune Fab (Ovine) antivenom to Crotalidae Immune F(ab)² (Equine) antivenom 3. Recognize treatment options for black widow spider bite
4:05 pm: Evaluation Instructions; Adjourn	
Home Study 	<p align="center">Immunized People 2020: An Immunization Update Kathryn N. Anderson, PharmD (1.0 hours, ACPE UAN 0062-0000-20-013-H06-P/T, knowledge-based)</p> <p><i>At the completion of this activity, the pharmacist will be able to:</i></p> <ol style="list-style-type: none"> 1. Identify strategies to improve immunization rates 2. Review recently published immunizations efficacy studies 3. Determine a patient's immunization needs based on disease states, exposures, and immunization history through a patient case
	<p><i>At the completion of this activity, the technician will be able to:</i></p> <ol style="list-style-type: none"> 1. Identify strategies to improve immunization rates 2. Recall risk factors for vaccine preventable diseases 3. Summarize updates to national immunization recommendations

Please contact us at CE@cop.sc.edu or 803-777-9979 with any questions!